PPARG and systemic sclerosis: These findings are consistent with the notion that PPAR-γ plays an endogenous antifibrotic role in the skin and suggest that therapies targeting the NCoR/PPAR- γ pathway and adipogenesis represent novel therapeutic approaches for SSc.